Evidence map›Paper›PMID 40694195›Full record

ReviewClinical reviews in allergy & immunology2025

UHRF1 in Immune Regulation and Diseases: Mechanisms and Therapeutic Implications.

Tingyue Guo, Yihui Ruan, Bo Wu, Shulan Sun, Hongxu Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tingyue GuoDepartment of Thoracic Surgery, Cancer Hospital of Dalian University of Technology (Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute), Shenyang, Liaoning, 110042, People's Republic of China.
Yihui RuanDepartment of Medical Record, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110042, People's Republic of China.
Bo WuDepartment of Thoracic Surgery, Cancer Hospital of Dalian University of Technology (Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute), Shenyang, Liaoning, 110042, People's Republic of China.
Shulan SunCentral Laboratory, Cancer Hospital of Dalian University of Technology (Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute), Shenyang, Liaoning, 110042, People's Republic of China. sunshulan@cancerhosp-ln-cmu.com.
Hongxu LiuDepartment of Thoracic Surgery, Cancer Hospital of Dalian University of Technology (Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute), Shenyang, Liaoning, 110042, People's Republic of China. hongxuliu@dlut.edu.cn.

Funding

National Science Foundation of China 82073286Outstanding Youth Foundation of Liaoning 2022-YQ-08Science and Technology Joint Programme by the Education Department of Liaoning Province 2023-MSLH-167
6 · The paper itself

Abstract

As a key epigenetic regulator, E3 ubiquitin-ligase ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) is essential for maintaining genomic stability. The aberrant activation of UHRF1 has been strongly implicated in cancer progression. Emerging evidence indicates that UHRF1 serves as a pivotal orchestrator of immune homeostasis. This review provides an overview of the impact of UHRF1 on both innate and adaptive immunity, highlighting its epigenetic and regulatory roles in the development and function of macrophages, T lymphocytes, and B lymphocytes. Crucially, the protective mechanisms of UHRF1 in autoimmune disorders while concurrently detailing its tumor-promoting functions are dissected. Finally, this review discusses the therapeutic challenges and future perspectives for targeting UHRF1 in autoimmune disorders and cancers.

Indexed as

Autoimmune DiseasesCCAAT-Enhancer-Binding ProteinsImmunomodulationNeoplasmsUbiquitin-Protein LigasesAdaptive ImmunityAnimalsDisease SusceptibilityEpigenesis, GeneticHumansImmunity, InnateMacrophagesT-LymphocytesCCAAT-Enhancer-Binding ProteinsUbiquitin-Protein LigasesUHRF1 protein, humanAdaptive immune systemCytokinesInnate immune systemUHRF1

Identifiers

PMID40694195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.